Editas Medicine, Inc., a leading genome editing company,
announced it has exclusively licensed intellectual property related
to new CRISPR technologies for human therapeutics that will enhance
and broaden the range of medicines the company can develop. These
global licensing agreements include intellectual property owned by
the Broad Institute of MIT and Harvard (Broad Institute), Harvard
University, Massachusetts Institute of Technology (MIT), Wageningen
University, the University of Iowa, and the University of Tokyo for
the new CRISPR genome editing system.

Some comments from our readers…“The articles are extremely timely and highly applicable”“I often find critical information not available elsewhere”“As in-house counsel, Mondaq’s service is of great value”